Sanofi and Regeneron Announce Marketing Authorization Application for Dupixent® (dupilumab) Accepted for Review by the EMA - Seite 4

Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (http://newsroom.regeneron.com) and its Twitter feed (http://twitter.com/regeneron).

Contacts Sanofi: Media Relations Jack Cox Tel: [phone] [e-mail]	Investor Relations George Grofik Tel: [phone] [e-mail]
Contacts Regeneron: Media Relations Ilana Tabak Tel: [phone] Mobile: [phone] [e-mail]	Investor Relations Manisha Narasimhan, Ph.D. Tel: [phone] [e-mail]

Press release (PDF)

---

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Sanofi via Globenewswire